Information Provided By:
Fly News Breaks for August 9, 2016
RARE
Aug 9, 2016 | 05:53 EDT
Piper Jaffray analyst Steven Breazzano raised his price target for Ultragenyx to $82 following the company's Q2 results. Ultragenyx has multiple clinical and regulatory catalysts in the second half of 2016, Breazzano tells investors in a post-earnings research note. He reiterates an Overweight rating on the name.
News For RARE From the Last 2 Days
There are no results for your query RARE